Table 1:
Characteristics and Treatment of Patients with Primary and Secondary Breast Cancer from the California Cancer Registry (1988–2014)
| Only primary Breast Cancer | Secondary Breast Cancer | |
|---|---|---|
| N= 107,751 | N= 1,147 | |
| Characteristics | N (%) | N (%) |
|
| ||
| Race/ethnicity | ||
| Non-Hispanic White | 59,430 (55.2) | 588 (51.3) |
| Non-Hispanic Black | 7,990 (7.4) | 118 (10.3) |
| Hispanic | 23,950 (22.2) | 303 (26.4) |
| Asian/Pacific Islander | 15,009 (13.9) | 137 (11.9) |
| Other/Unknown | 1,372 (1.3) | 1 (0.1) |
|
| ||
| Age at Diagnosis | ||
| 12–24 | 320 (0.3) | 5 (0.4) |
| 25–29 | 2,041 (1.9) | 19 (1.7) |
| 30–34 | 6,915 (6.4) | 78 (6.8) |
| 35–39 | 15,468 (14.4) | 268 (23.4) |
| 40–44 | 30,333 (28.2) | 430 (37.5) |
| 45–50 | 52,674 (48.9) | 347 (30.3) |
|
| ||
| Year of diagnosis | ||
| 1988–1994 | 21,639 (20.1) | 62 (5.4) |
| 1995–2001 | 26,914 (25.0) | 251 (21.9) |
| 2002–2008 | 31,180 (28.9) | 412 (35.9) |
| 2009–2014 | 28,018 (26.0) | 422 (36.8) |
|
| ||
| Neighborhood socioeconomic status | ||
| Low SES | 53,483 (49.6) | 551 (48.0) |
| High SES | 54,268 (50.4) | 596 (52.0) |
|
| ||
| AJCC Stage | ||
| Stage I | 35,991 (33.4) | 522 (45.5) |
| Stage II | 45,942 (42.6) | 355 (31.0) |
| Stage III | 12,886 (12.0) | 117 (10.2) |
| Stage IV | 4,555 (4.2) | 85 (7.4) |
| Unknown | 8,377 (7.8) | 68 (5.9) |
|
| ||
| Chemotherapy | ||
| Yes | 66,975 (62.2) | 635 (55.4) |
| No/Unknown | 40,776 (37.8) | 512 (44.6) |
| Radiation | ||
| Yes | 49,032 (45.5) | 302 (26.3) |
| No/Unknown | 58,719 (54.5) | 845 (73.7) |
| Surgery | ||
| Lumpectomy | 46,960 (43.6) | 321 (28.0) |
| Mastectomy | 54,092 (50.2) | 723 (63.0) |
| None | 5,960 (5.5) | 99 (8.6) |
| Unknown | 739 (0.7) | 4 (0.3) |
|
| ||
| Tumor grade | ||
| Grade I | 13,390 (12.4) | 112 (9.8) |
| Grade II | 36,023 (33.4) | 328 (28.6) |
| Grade III | 42,538 (39.5) | 566 (49.3) |
| Undifferentiated | 2,349 (2.2) | 33 (2.9) |
| Unknown | 13,451 (12.5) | 108 (9.4) |
|
| ||
| Histology | ||
| Ductal | 83,516 (77.5) | 897 (78.2) |
| Lobular | 14,644 (13.6) | 142 (12.4) |
| Other | 9,591 (8.9) | 108 (9.4) |
|
| ||
| Tumor size | ||
| T1a: ≤0.5cm | 5,925 (5.5) | 112 (9.8) |
| T1b: >0.5–1cm | 11,763 (10.9) | 179 (15.6) |
| T1c: >1–2cm | 33,970 (31.5) | 359 (31.3) |
| T2: >2–5cm | 38,180 (35.4) | 322 (28.1) |
| T3: >5.00 cm | 9,421 (8.7) | 70 (6.1) |
| Diffuse | 1,725 (1.6) | 18 (1.6) |
| Other | 6,767 (6.3) | 87 (7.6) |
|
| ||
| Regional lymph node involvement | ||
| Positive | 46,089 (42.8) | 327 (28.5) |
| Negative | 57,562 (53.4) | 754 (65.7) |
| Unknown | 4,100 (3.8) | 66 (5.8) |
|
| ||
| Regional nodes examined | ||
| Sentinel Lymph Node Biopsy (SLNB) | 31,986 (29.7) | 413 (36.0) |
| Axillary Lymph Node Dissection (ALND) | 65,484 (60.8) | 418 (36.4) |
| No nodes examined/unknown | 10,281 (9.5) | 316 (27.6) |
|
| ||
| Estrogen Receptor(ER)status | ||
| Positive | 63,749 (59.2) | 583 (50.8) |
| Negative | 23,926 (22.2) | 415 (36.2) |
| Unknown | 20,076 (18.6) | 149 (13.0) |
| Progesterone Receptor(PR)status | ||
| Positive | 57,160 (53.0) | 510 (44.5) |
| Negative | 28,884 (26.8) | 479 (41.8) |
| Unknown | 21,707 (20.1) | 158 (13.8) |
| HER-2* | ||
| Positive | 12,056 (21.9) | 151 (19.1) |
| Negative | 37,222 (67.6) | 541 (68.6) |
| Unknown | 5,800 (10.5) | 97 (12.3) |
|
| ||
| Vital status | ||
| Alive | 83,346 (77.4) | 799 (69.7) |
| Death from breast cancer | 20,558 (19.1) | 298 (26.0) |
| Death from other causes | 3.847 (3.6) | 50 (4.4) |
*
HER-2 data is limited to 2003+ diagnoses, N (only primary) = 55,078, N (secondary) = 789
SES=Socioeconomic status; AJCC=American Joint Committee on Cancer; HER-2=human epidermal growth factor receptor-2.